IM and AS donor descriptions
| Donor . | Day(s) after diagnosis . | PBMC count† . | CD8 (%)‡ . | CD4 (%)1-153 . | Anti-VCA IgM . | Anti-VCA IgG . | Anti-EBNA IgG . | Health status . | Infection stage1-155 . |
|---|---|---|---|---|---|---|---|---|---|
| IM1 | 0 | 6 × 106/mL | 77 | 8 | + | − | − | IM symptoms | Primary |
| 132 | 1 × 106/mL | ND | ND | − | + | + | Recovery | Persistent | |
| IM2 | 0 | 2.3 × 106/mL | 70 | 24 | + | + | − | IM symptoms | Primary |
| 115 | 1 × 106/mL | ND | ND | − | − | + | Recovery | Persistent | |
| IM3* | 0 | 10 × 106/mL | 67 | 24 | + | − | − | IM symptoms | Primary |
| IM4* | 0 | 6 × 106/mL | 53 | 7 | + | + | − | IM symptoms | Primary |
| AS1 | 0 | 1 × 106/mL | ND | ND | + | + | − | Asymptomatic | Primary |
| 300 | 1 × 106/mL | ND | ND | − | + | − | Asymptomatic | Persistent | |
| AS2 | 0 | 0.8 × 106/mL | 32 | 14 | + | + | − | Asymptomatic | Primary |
| 73 | 1.6 × 106/mL | 48 | 24 | − | + | − | Asymptomatic | Persistent | |
| AS3 | 0 | 1.5 × 106/mL | 27 | 53 | + | − | − | Asymptomatic | Primary |
| 17 | 1.2 × 106/mL | 28 | 45 | + | − | − | Asymptomatic | Primary | |
| AS4* | 0 | 2 × 106/mL | ND | ND | + | − | − | Asymptomatic | Primary |
| Donor . | Day(s) after diagnosis . | PBMC count† . | CD8 (%)‡ . | CD4 (%)1-153 . | Anti-VCA IgM . | Anti-VCA IgG . | Anti-EBNA IgG . | Health status . | Infection stage1-155 . |
|---|---|---|---|---|---|---|---|---|---|
| IM1 | 0 | 6 × 106/mL | 77 | 8 | + | − | − | IM symptoms | Primary |
| 132 | 1 × 106/mL | ND | ND | − | + | + | Recovery | Persistent | |
| IM2 | 0 | 2.3 × 106/mL | 70 | 24 | + | + | − | IM symptoms | Primary |
| 115 | 1 × 106/mL | ND | ND | − | − | + | Recovery | Persistent | |
| IM3* | 0 | 10 × 106/mL | 67 | 24 | + | − | − | IM symptoms | Primary |
| IM4* | 0 | 6 × 106/mL | 53 | 7 | + | + | − | IM symptoms | Primary |
| AS1 | 0 | 1 × 106/mL | ND | ND | + | + | − | Asymptomatic | Primary |
| 300 | 1 × 106/mL | ND | ND | − | + | − | Asymptomatic | Persistent | |
| AS2 | 0 | 0.8 × 106/mL | 32 | 14 | + | + | − | Asymptomatic | Primary |
| 73 | 1.6 × 106/mL | 48 | 24 | − | + | − | Asymptomatic | Persistent | |
| AS3 | 0 | 1.5 × 106/mL | 27 | 53 | + | − | − | Asymptomatic | Primary |
| 17 | 1.2 × 106/mL | 28 | 45 | + | − | − | Asymptomatic | Primary | |
| AS4* | 0 | 2 × 106/mL | ND | ND | + | − | − | Asymptomatic | Primary |
ND indicates not done.
No follow-up bleed was available.
Normal range for healthy control donors, 1-2 × 106 cells/mL blood.
Normal range for healthy control donors, 19% to 48% PBMCs.
Normal range for healthy control donors, 28% to 58% PBMCs.
Based on serologic profile (see “Materials and methods”).